Chan S, Erikainen S (2018) What’s in a name? The politics of ‘precision medicine’. Am J Bioeth
18:50–52. https://doi.org/10.1080/15265161.2018.1431324
Cheung H, Lee T, Rennert OM, Chan W (2009) DNA methylation of cancer genome. Birth Defects
Res C Embryo Today 87(4):335–350. https://doi.org/10.1002/bdrc.20163
Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ, Liu JO (2007) Inhibition of angiogenesis by the
antifungal drug itraconazole. ACS Chem Biol 2:263–270. https://doi.org/10.1021/cb600362d
Cohrs RJ, Martin T, Ghahramani P, Bidaut L, Higgins PJ, Shahzad A (2015) Translational medicine
definition by the European Society for Translational Medicine. New Horiz Transl Med 2(3):
86–88. https://doi.org/10.1016/j.nhtm.2014.12.002
Cook D, Brown D, Alexandar R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014)
Lessons learned from the fate of Astra-Zeneca’s drug pipeline: a five dimensional network. Nat
Rev Drug Discov 13:419–431. https://doi.org/10.1038/nrd4309. Epub 2014 May 16
Day M, Rutkowski JL, Feuerstein GZ (2009) Translational medicine—a paradigm shift in modern
drug discovery and development: the role of biomarkers. In: Guzmán CA, Feuerstein GZ (eds)
Pharmaceutical biotechnology. Advances in experimental medicine and biology, vol vol 655.
Springer, New York. https://doi.org/10.1007/978-1-4419-1132-2_1
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovations in the pharmaceutical industry: new
estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.
01.012
Eknoyan G (2007) Looking at the urine: the renaissance of an unbroken tradition. World Kidney
Forum 49(6):865–872. https://doi.org/10.1053/j.ajkd.2007.04.003
Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness VG, Baughn LB, Linden MA (2014) Utilization
of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple
myeloma. J Cancer 5(9):720–727. https://doi.org/10.7150/jca.9864
FDA 2020 New drugs at FDA: CDER’s new molecular entities and new therapeutic biological
products. Available from https://www.fda.gov/drugs/development-approval-process-drugs/
new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.
Accessed 28 Aug 2020
Fyfe NR (2019) Evidence-based policing: translating research into practice. Policy Soc 29:1126–
1127. https://doi.org/10.1080/10439463.2019.1678621
Hsueh C, Liu D, Wang H (2013) Novel biomarkers for diagnosis, prognosis, targeted therapy and
clinical trials. Biomark Res 1:1. https://doi.org/10.1186/2050-7771-1-1
Kagan JM, Sanchez AM, Landay A, Denny TN (2015) A brief chronicle of CD4 as a biomarker for
HIV/AIDS: a tribute to the memory of John L Fahey. Forum Immunopathol Dis Ther 6(1–2):
57–65. https://doi.org/10.1615/ForumImmunDisTher.2016014169
Kang Z, Liu Y, Xu L, Long Z, Huang D, Yang Y, Liu B, Feng J, Pan Y, Yan J, Liu K (2016) The
Philadelphia chromosome in leukemogenesis. Chin J Cancer 35:48. https://doi.org/10.1186/
s40880-016-0108-0
Kurani S, Theel E, Worisek AG (2017) Diagnostic testing for Zika: observing rapid translation
during a public health emergency. Clin Transl Sci 11(2):103–105. https://doi.org/10.1111/cts.
12529
Lauschke VM, Milani L, Ingelman SM (2018) Pharmacogenomic biomarkers for improved drug
therapy-recent progress and future developments. AAPS J 20:4. https://doi.org/10.1208/s12248-
017-0161-x
Matsui S (2013) Genomic biomarkers for personalized medicine: development and validation in
clinical studies. Comput Math Methods Med, Article ID 865980. https://doi.org/10.1155/2013/
865980
Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182–188. https://doi.org/
10.1602/neurorx.1.2.182
Navin NE (2015) The first five years of single-cell cancer genomics and beyond. Genome Res 25:
1499–1507. https://doi.org/10.1101/gr.191098.115
Naylor S, Kauppi MJ, Schonfeld JM (2015) Therapeutic drug repurposing, repositioning and
rescue: part III: market exclusivity using intellectual property and regulatory pathways. Drug
Discov World 16(3):62–69
9
Biomarker-Based Drug Discovery with Reverse Translational Approach
139